Please login to the form below

Not currently logged in
Email:
Password:

Epclusa

This page shows the latest Epclusa news and features for those working in and with pharma, biotech and healthcare.

Merck & Co pulls out of hepatitis C R&D as market shrinks

Merck & Co pulls out of hepatitis C R&D as market shrinks

In the same period, Gilead’s HCV portfolio of Harvoni (sofosbuvir/ledipasvir), Epclusa (sofosbuvir/velpatasvir) and Sovaldi (sofosbuvir) brought in $5.44bn, down from around $8.3bn in the first half

Latest news

  • Gilead gets OK for three-in-one hep C therapy in US Gilead gets OK for three-in-one hep C therapy in US

    The single-tablet triple therapy contains NS5B polymerase inhibitor sofosbuvir and NS5A inhibitor velpatasvir - the two active ingredients in Gilead's recently-approved two-drug HCV combination Epclusa - as well as ... Sovaldi and follow-ups Harvoni and

  • Two new hepatitis C therapies fast-tracked in Europe Two new hepatitis C therapies fast-tracked in Europe

    It is dosed once daily as three oral tablets and is being billed as a rival to Epclusa, which is dosed over 12 weeks in all patients. ... Analysts at Leerink have previously predicted that combined sales of Harvoni, Sovaldi and Epclusa will be $2.5bn a

  • Gilead files hepatitis C salvage regimen in US Gilead files hepatitis C salvage regimen in US

    Gilead files hepatitis C salvage regimen in US. Seeks FDA approval for combination of Epclusa and voxilaprevir. ... The SVR rates were comparable between the new regimen and Epclusa in both trials.

  • SMC approves Opdivo combo as first-line skin cancer treatment SMC approves Opdivo combo as first-line skin cancer treatment

    SMC approves Opdivo combo as first-line skin cancer treatment. Also backs Gilead’ s Epclusa, Baxalta’ s Oncaspar, AZ’ s Lynparza and Amicus’ Galafold. ... Meanwhile, Gilead Sciences' chronic hepatitis C virus infection therapy Epclusa

  • Torrid times at Gilead lead to calls for a major M&A deal Torrid times at Gilead lead to calls for a major M&A deal

    HIV portfolio sales down almost 10% to $7.5bn despite strong $533m start for Epclusa. ... start for latest entrant Epclusa (sofosbuvir and velpatasvir), which contributed $533m in the quarter.

More from news
Approximately 8 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
bmore group

OUR PROMISE: BETTER HEALTH FROM TRIAL TO TREATMENT.We are a full service, independent network of specialist agencies under one roof....

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics